Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Objective Assessment of Metabolic Monitoring in Patients Treated With Seroquel® or Seroquel® XR/Quetiapine Fumarate: Use of IMS Disease Analyzer to Assess Physician Behaviour in the UK and Germany

NCT01793324 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01793324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01793324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Objective Assessment of Metabolic Monitoring in Patients Treated With Seroquel® or Seroquel® XR/Quetiapine Fumarate: Use of IMS Disease Analyzer to Assess Physician Behaviour in the UK and Germany
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 30, 2012
Completion date
June 30, 2013
Enrollment
6,153 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, major depressive disorder, schizophrenia